Navigation Links
Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Date:8/6/2013

strative expenses. As of June 30, 2013, Orexigen had $55.8 million in cash and cash equivalents and an additional $40.2 million in marketable securities, for a total of $96.0 million.

Product candidates: Contrave (32 mg naltrexone sustained-release (SR)/360 mg bupropion SR) for the treatment of obesity: In 2012, Orexigen screened more than 13,000 patients, enrolled more than 10,400 and ultimately completed recruitment of the Light Study with approximately 8,900 randomized patients. The primary objective of the double-blind, randomized, placebo-controlled Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA (United States Food and Drug Administration), is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. An interim analysis and NDA resubmission is planned once the independent Data Monitoring Committee (DMC) has determined that sufficient information has been gathered for the analysis that would include at least 87 adjudicated major adverse cardiovascular events (MACE). Orexigen enrolled into the Light Study a patient population that the company predicted would have an annualized MACE rate between 1% and 2%. Orexigen is preparing to be ready to conduct the interim analysis and resubmit the Contrave NDA in the remaining months of 2013. Orexigen has licensed North American commercial rights to Takeda Pharmaceuticals. Orexigen owns Contrave rights throughout the rest of the world and intends to license commercial rights outside North America.

Empatic™, a fixed dose combination of bupropion SR and zonisamide SR, for the treatment of obesity: In a series of discussions with the FDA on the continued development of Empatic, the FDA stated that Phase 3 data for Empatic may be sufficient to support submission of an NDA without data from a cardiovascular outcomes trial. The FDA indicated that as long as the placebo-subtracted changes in body weight, blood pressure
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Unigenes Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
2. Orexigen Therapeutics to Present at the Jefferies 2012 Global Healthcare Conference
3. Orexigen Therapeutics to Present at the JMP Securities Healthcare Conference
4. Orexigen Therapeutics Announces the Light Study is Enrolling Faster than Originally Projected
5. Orexigen Therapeutics Schedules August 7, 2012 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2012
6. Orexigen Therapeutics Reports Financial Results for the Second Quarter Ended June 30, 2012
7. Orexigen Therapeutics Announces Presentations at Upcoming Investor Conferences
8. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
9. Orexigen Therapeutics Reports Financial Results for the Third Quarter Ended September 30, 2012
10. Orexigen Therapeutics To Host Analyst Day Event on December 18, 2012
11. Orexigen Therapeutics to Present at Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Research and Markets has announced the addition ... report to their offering. Multiple ... in demyelination, axonal transection, and neurodegeneration. The myelin sheath ... immune system, which targets neurons within the central nervous ... which the damage of the myelin sheath causes disruption ...
(Date:8/29/2014)... Aug. 29, 2014  Pacific Medical Data Solutions is ... website design . The main website, along with the ... company,s new services and content relevant to the medical ... streamlined design, viewers can now better understand how PMDS ... practices and create a more visible platform about medical ...
(Date:8/29/2014)... , Aug. 29, 2014 Research and ... Orthopedic Soft Tissue Repair Devices Market 2014-2018" report ... are the mass of cells that connect, support, or ... tissues such as tendons, ligaments, cartilage, fascia, and other ... of these tissues with age result in wear and ...
Breaking Medicine Technology:Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 2Global Multiple Sclerosis Drugs Market 2014-2018: Key Vendors are Bayer, Biogen Idec, Merck Serono, Novartis and Teva Pharmaceutical 3PMDS Announces New Website 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3
... 2011 Brain Plasticity Inc. (BPI), a technology incubator ... that harness the basic principles of brain plasticity to ... disorders, was recently awarded a $2 million grant from ... The grant will fund a two-year clinical trial of ...
... recent paper published in the Journal of Glaucoma ... a fast, objective method to screen for functional damage in ... significantly decreases test duration and provides less subjectivity in evaluating ... out at New York Eye and Ear Infirmary (New York, ...
Cached Medicine Technology:U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 2U.S. Department of Defense Awards $2 Million to Brain Plasticity Inc. to Study Impact of Brain Training for Traumatic Brain Injuries 3New Test to Screen for Glaucoma Damage 2
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- Astronauts ... travel appears to disrupt human immune systems, a new ... on any long missions to asteroids, the moon and ... or flu while in space can be dangerous, NASA ... immune cells in the blood of International Space Station ...
(Date:8/29/2014)... FRIDAY, Aug. 29, 2014 (HealthDay News) -- If you have ... more serious treatment later, an expert says. A bunion ... big toe when bone or tissue moves out of place ... untreated, bunions can cause debilitating pain and may require surgery ... at CentraState Medical Center in Freehold, N.J. To prevent ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 A ... hearing wellness solutions, is on its way to the ... the San Diego Convention Center to exhibit and demonstrate ... work in high-noise industrial environments. Etymotic’s safety earphones and ... wearable technology devices at the show. , The ...
(Date:8/29/2014)... 2014 LiveOps, Inc., the global leader ... announced that LiveOps has been selected as a call ... of Strength Telethon for the third year in a ... awareness to support MDA’s mission to help children and ... fatal muscle disease. This year’s program includes performances by ...
(Date:8/29/2014)... cancer patients lacking knowledge about the disease have difficulty ... quality of care and long-term results, new research suggests. ... age of 63. All were newly diagnosed with localized ... associated with greater difficulty deciding which treatment to choose ... the study found. "For prostate cancer, there is ...
Breaking Medicine News(10 mins):Health News:Spaceflight Might Weaken Astronauts' Immune Systems 2Health News:Take Steps to Control Bunions 2Health News:Etymotic’s Safe Listening Earphones and Earplugs Headed For The 2014 NSC Safety Expo 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 2Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 3Health News:LiveOps Supports Muscular Dystrophy Association Show of Strength Telethon 4Health News:Faced With Prostate Cancer, It Helps to Know the Enemy 2
... ... with AiRISTA to provide Wi-Fi-based RFID solutions. , ... Sparks, Maryland (PRWEB) September 14, 2009 ... (DCC) to promote, distribute, implement and support AiRISTA,s solutions and technologies ( www.AiRISTA.com ...
... works in different way than standard medicines , SUNDAY, ... people whose high blood pressure cannot be controlled by ... researchers report. , Substantial reductions in blood pressure were ... people who were still hypertensive despite trying three or ...
... ... has been awarded the prestigious Gold certification from Cisco systems for ... The Certification recognizes High Point,s expert level of achievement for advanced ... Data Center. Gold Certified Partners are considered extensions of Cisco,s support ...
... the first ever found to prevent cartilage loss from osteoarthritis ... cartilage that has been lost to osteoarthritis, according to an ... American Society for Bone and Mineral Research in Denver. While ... osteoarthritis that develops following knee injuries, according to the study ...
... say they,ll donate than do, leaving long waits for transplants ... and large say they support the idea of donating some ... lives, reality presents a different picture. , Just 38 percent ... organ and tissue donors, according to a report this year ...
... , FRAMINGHAM, Mass., Sept. 11 Philips Lifeline ... subscribers of its personal emergency response service to alert users of ... is used primarily by seniors living independently in their homes who ... button" worn on the body, users connect to a remote monitoring ...
Cached Medicine News:Health News:AiRISTA's Unified Visibility Solutions Bringing Together Wi-Fi RTLS, And Telemetry Offer Enormous Business Opportunities To Systems Integrators 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 2Health News:Drug Offers Hope Against Tough-to-Treat Hypertension 3Health News:High Point Solutions has Been Awarded the Prestigious Gold Certification from Cisco Systems 2Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 2Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 3Health News:Hormone promises to keep joint injuries from causing long-term osteoarthritis 4Health News:For Organ Donation, Intent and Reality Don't Align 2Health News:For Organ Donation, Intent and Reality Don't Align 3Health News:Lifeline Issues Safety Notice to Subscribers 2
Skin Tone External Eyelid Weights...
To prevent retraction of the conjunctival cul-de-sacs without touching the cornea....
Bioceramic orbital implants insert easily into orbital socket and will not cling to surrounding tissue. Improved interconnectivity between pores enhances vascularization. Implants may be easily drill...
...
Medicine Products: